Tsao C.-I.NAI-KUAN CHOUNAI-HSIN CHIHSI-YU YUYIH-SHARNG CHENCHIH-HSIEN WANGKo W.-J.SHYR-CHYR CHENSHOEI-SHEN WANG2021-05-062021-05-0620100041-1345https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955499374&doi=10.1016%2fj.transproceed.2010.02.053&partnerID=40&md5=afe6947be63547b7487b8217f7f15bb5https://scholars.lib.ntu.edu.tw/handle/123456789/560046Introduction Survival in patients with refractory heart failure greatly improves after heart transplantation (HTx). Objective To evaluate the rate of unplanned readmission within the first year post-HTx and the causes of such readmission. Patients and Methods From January 2005 to June 2008, the 112 patients who underwent HTx were regularly followed up at our hospital. A protocol biopsy was performed every week during the first month, then every 3 months during the first year. Any unplanned readmission was discussed in detail in a transplantation meeting. Data were collected from review of medical records. Results The rate of unplanned readmission was 19.3% in 2005, 21.5% in 2006, 22.2% in 2007, and 20.3% in 2008. Infection was the primary cause leading to unplanned readmission in 2005 (51.5%), 2006 (42.9%), and 2008 (30.7%). Rejection was the primary cause leading to readmission in 2007 (40%). Other causes included fluid retention, pericardial effusion, anemia, and systemic diseases. Conclusion To reduce unplanned readmissions and to promote quality of life and long-term survival, health professionals must meticulously monitor the adverse effects of treatments including immunosuppression agents and concomitantly used medications. ? 2010 Elsevier Inc.en[SDGs]SDG3basiliximab; cyclosporin; hybrid protein; immunosuppressive agent; lymphocyte antibody; monoclonal antibody; tacrolimus; article; biopsy; follow up; graft rejection; heart transplantation; hospital readmission; human; immunology; pathology; patient care planning; pericardial effusion; retrospective study; statistics; Taiwan; time; Antibodies, Monoclonal; Antilymphocyte Serum; Biopsy; Cyclosporine; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Immunosuppressive Agents; Patient Care Planning; Patient Readmission; Pericardial Effusion; Recombinant Fusion Proteins; Retrospective Studies; Tacrolimus; Taiwan; Time Factorsconference paper10.1016/j.transproceed.2010.02.053204302122-s2.0-77955499374